IPG1094

IPG1094 is an orally bioavailable, selective, and potent small molecule inhibitor of the pro-inflammatory cytokine macrophage migration inhibitory factor (MIF). It acts by binding to and inhibiting the tautomerase activity of MIF, which plays a key role in inflammatory and immune responses. By inhibiting MIF's tautomerase domain, IPG1094 disrupts its interaction with the CD74 receptor complex on myeloid cells, leading to apoptosis of activated M1 macrophages and subsequent resolution of inflammation. This mechanism underlies its potential anti-inflammatory, immunomodulatory, and antineoplastic activities. The drug is being developed primarily for autoimmune diseases such as systemic lupus erythematosus (SLE), lupus nephritis, multiple sclerosis, psoriasis, inflammatory bowel disease (IBD), as well as various cancers including melanoma, multiple myeloma, colon cancer, advanced solid tumors (such as brain glioma), triple-negative breast cancer, head and neck cancer, small-cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), and lung cancer with brain metastasis. Developed by Nanjing Immunophage Biotech Co., Ltd., clinical trials have demonstrated favorable safety margins and pharmacokinetic properties[1][2][3][5][7].